 |
BioWorld-International-2007-12-19
Light-Activated Cancer Therapy Could Have Glowing Prospects
Pharming Shares Sink On CHMP Rebuff For Rhucin
Shares in Pharming Group NV sank by more than 65 percent on news that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on a marketing authorization application for its lead drug, the hereditary angioedema treatment Rhucin. (BioWorld International)
Santaris Raises €20M For LNA-Based Drug Portfolio
No Abstract
BioWorld International Correspondent
Santaris Pharma A/S raised €20.4 million (US$29.4 million) in a new investment round led by Gilde Healthcare Partners BV, of Utrecht, the Netherlands, which contributed €7.5 million of the total.